tradingkey.logo
tradingkey.logo

Amneal Pharmaceuticals Inc

AMRX
View Detailed Chart
11.850USD
-0.210-1.74%
Close 03/27, 16:00ETQuotes delayed by 15 min
794.04MMarket Cap
51.54P/E TTM

Amneal Pharmaceuticals Inc

11.850
-0.210-1.74%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.74%

5 Days

+0.17%

1 Month

-14.19%

6 Months

+21.54%

Year to Date

-5.95%

1 Year

+43.12%

View Detailed Chart

Key Insights

Amneal Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 31 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.50.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amneal Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
31 / 157
Overall Ranking
104 / 4542
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Amneal Pharmaceuticals Inc Highlights

StrengthsRisks
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.12% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 51.54, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 154.72M shares, increasing 0.04% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 1.67M shares of this stock.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
16.500
Target Price
+36.82%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Amneal Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Amneal Pharmaceuticals Inc Info

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Ticker SymbolAMRX
CompanyAmneal Pharmaceuticals Inc
CEOPatel (Chintu)
Websitehttps://amneal.com/
KeyAI